Total Payments
$13,624
2018 Payments
$5,454
Companies
17
Transactions
50
Payment Breakdown by Category
Consulting$5,900 (43.3%)
Research$5,270 (38.7%)
Travel$1,464 (10.7%)
Food & Beverage$818.00 (6.0%)
Education$170.94 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,900 | 2 | 43.3% |
| Unspecified | $5,270 | 2 | 38.7% |
| Travel and Lodging | $1,464 | 8 | 10.7% |
| Food and Beverage | $818.00 | 36 | 6.0% |
| Education | $170.94 | 2 | 1.3% |
Payments by Type
General
$8,353
48 transactions
Research
$5,270
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $5,270 | 2 | $0 (2018) |
| Gilead Sciences, Inc. | $4,528 | 10 | $0 (2018) |
| Genentech USA, Inc. | $3,204 | 10 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $177.53 | 3 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $102.75 | 7 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $90.75 | 1 | $0 (2017) |
| Exelixis Inc. | $42.67 | 3 | $0 (2018) |
| Helsinn Therapeutics (U.S.), Inc. | $39.68 | 3 | $0 (2018) |
| Millennium Pharmaceuticals, Inc. | $39.15 | 2 | $0 (2017) |
| GENZYME CORPORATION | $26.52 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2018 | $5,454 | 11 | Eli Lilly and Company ($5,241) |
| 2017 | $8,169 | 39 | Gilead Sciences Inc ($4,515) |
All Payment Transactions
50 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/27/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.27 | General |
| Category: Oncology | ||||||
| 03/22/2018 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Education | In-kind items and services | $74.99 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2018 | AstraZeneca Pharmaceuticals LP | IRESSA (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Oncology | ||||||
| 03/04/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 02/27/2018 | MEDIVATION FIELD SOLUTIONS LLC | XTANDI (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.52 | General |
| 02/26/2018 | Helsinn Therapeutics (U.S.), Inc. | ALOXI (Drug), ZYKADIA, AKYNZEO | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: ONCOLOGY | ||||||
| 02/19/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: Oncology | ||||||
| 01/30/2018 | Eli Lilly and Company | CYRAMZA (Drug) | — | Cash or cash equivalent | $5,241.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTREATED PATIENTS WITH EGFR MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER • Category: Oncology | ||||||
| 01/22/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Oncology | ||||||
| 01/16/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $11.30 | General |
| Category: Oncology | ||||||
| 12/19/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $9.45 | General |
| Category: Oncology | ||||||
| 12/12/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Oncology | ||||||
| 12/07/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $90.75 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2017 | Helsinn Therapeutics (U.S.), Inc. | ALOXI (Drug), ZYKADIA, AKYNZEO | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2017 | Genentech USA, Inc. | GAZYVA (Biological), Rituxan | Food and Beverage | In-kind items and services | $9.65 | General |
| Category: BioOncology | ||||||
| 11/07/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $4.13 | General |
| 11/06/2017 | Amgen Inc. | Neulasta (Biological), NEUPOGEN, Vectibix | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Oncology | ||||||
| 10/30/2017 | Gilead Sciences Inc | Zydelig (Drug) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: ONC | ||||||
| 10/30/2017 | Gilead Sciences Inc | Zydelig (Drug) | Food and Beverage | In-kind items and services | $83.33 | General |
| Category: ONC | ||||||
| 10/30/2017 | Gilead Sciences Inc | Zydelig (Drug) | Travel and Lodging | In-kind items and services | $12.00 | General |
| Category: ONC | ||||||
| 10/09/2017 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: Oncology | ||||||
| 10/07/2017 | Gilead Sciences Inc | Zydelig (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONC | ||||||
| 10/07/2017 | Gilead Sciences Inc | Zydelig (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONC | ||||||
| 10/06/2017 | Gilead Sciences Inc | Zydelig (Drug) | Travel and Lodging | In-kind items and services | $419.40 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTREATED PATIENTS WITH EGFR MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $5,270 | 2 |
About Dr. Robert Boone, MD
Dr. Robert Boone, MD is a Specialist healthcare provider based in Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033220520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Boone, MD has received a total of $13,624 in payments from pharmaceutical and medical device companies, with $5,454 received in 2018. These payments were reported across 50 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($5,900).
Ad
Practice Information
- Specialty Specialist
- Location Bend, OR
- Active Since 08/31/2006
- Last Updated 06/28/2014
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1033220520
Products in Payments
- CYRAMZA (Drug) $5,270
- Zydelig (Drug) $4,510
- TECENTRIQ (Biological) $3,184
- JEVTANA (Drug) $108.10
- ZALTRAP (Drug) $95.95
- KEYTRUDA (Biological) $90.75
- IMFINZI (Drug) $55.81
- Cabometyx (Drug) $42.67
- ALOXI (Drug) $39.68
- IRESSA (Drug) $35.76
- NINLARO (Drug) $34.79
- Neulasta (Biological) $22.15
- XTANDI (Drug) $18.90
- OPDIVO (Biological) $15.27
- TAGRISSO (Drug) $11.18
- GAZYVA (Biological) $9.65
- Avastin (Biological) $5.28
- Optune (Device) $4.46
- Perjeta (Biological) $4.33
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Bend
Dr. Andrew Jones, Md, MD
Specialist — Payments: $301,437
Specialist $301,437
Dr. Timothy Beard, M.d,, M.D,
Specialist — Payments: $200,366
Specialist $200,366
Stephen Kornfeld, Md, MD
Specialist — Payments: $52,446
Specialist $52,446
Dr. Anthony Hadden, M.d, M.D
Specialist — Payments: $45,603
Specialist $45,603
Michael Mastrangelo, M.d, M.D
Specialist — Payments: $16,076
Specialist $16,076
Dr. Robert Quinn, Md, MD
Specialist — Payments: $11,528
Specialist $11,528